Al Bentley
4 min read
enGene Therapeutics has seen analyst price targets shift toward a tighter band around about $4 to $6 per share, underpinned by an updated fair value estimate that moves from $3.29 to $3.86. Recent Street research links these changes to how analysts interpret the latest detalimogene LEGEND data, the Adstiladrin comparison, and the evolving regulatory path toward a potential BLA submission. As you read on, you will see how to track this evolving narrative and what to watch as new data and regulatory updates emerge.
Stay updated as the Fair Value for enGene Therapeutics shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on enGene Therapeutics.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Analysts at Wells Fargo, Piper Sandler and Leerink have all shifted to positive ratings on enGene Therapeutics, with price targets now grouped in the US$4 to US$6 range. This frames how they see risk and reward after the latest LEGEND data.
-
Piper Sandler points to improved efficacy measures in the detalimogene LEGEND cohort and views the evolving data as comparable to Adstiladrin. They see this as supportive for enGene’s potential positioning in non muscle invasive bladder cancer.
-
Wells Fargo highlights what it views as increasing confidence in the regulatory path, citing maturing durability data and a safety profile it describes as favorable, along with the recent pre BLA interactions.
-
Leerink flags an any time complete response rate of 56% as sitting within the range of approved therapies and describes the updated profile as taking what it saw as a worst case scenario off the table. This informs its higher US$5 target.
🐻 Bearish Takeaways
-
Street research still points to open questions around execution, including the eventual timing of a launch, pricing, reimbursement decisions and early physician adoption. Leerink expects these factors to shape how investors view enGene Therapeutics from here.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 3 risks for enGene Therapeutics. See which could impact your investment.
What’s in the News
-
enGene Therapeutics reported interim LEGEND Cohort 1 data in high risk, BCG unresponsive non muscle invasive bladder cancer with carcinoma in situ, with a 54% complete response rate at any time and a 3.2% rate of progression to muscle invasive disease.
-
The company plans to share updated Cohort 1 data on key primary and secondary regulatory endpoints, including complete response at any time and 12 month duration of response. It also expects a pre BLA meeting with the FDA in the fourth quarter of 2026 ahead of a planned BLA filing initiation before year end.
-
enGene Therapeutics is enrolling an additional LEGEND cohort that combines detalimogene with a brief bladder rinse using the FDA approved surfactant polidocanol in high risk, BCG unresponsive patients with carcinoma in situ.
-
Preclinical work shared by the company linked surfactant pretreatment to higher IL 12 expression and broader nanoparticle distribution in animal models, and enGene Therapeutics was removed from the S&P Global BMI Index.
